A Phase 2, Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Voreloxin (Vosaroxin) Injection in Patients Equal to or Greater Than 60 Years of Age With Previously Untreated Acute Myeloid Leukemia
Latest Information Update: 03 Jul 2017
At a glance
- Drugs Vosaroxin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms REVEAL-1
- Sponsors Sunesis Pharmaceuticals
- 24 Nov 2014 Results published in a Sunesis Pharmaceuticals media release and also published online in the British Journal of Haematology.
- 26 May 2010 Status changed from active, no longer recruiting to completed.
- 24 May 2010 Status cahnge from active, no longer recruiting to completed